翰宇药业：2025年半年度净利润约1.45亿元

Core Viewpoint - Hanyu Pharmaceutical reported significant growth in its half-year performance for 2025, indicating a strong recovery and positive financial trajectory compared to the previous year [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 549 million yuan, representing a year-on-year increase of 114.86% [2] - The net profit attributable to shareholders for the same period was around 145 million yuan, with a basic earnings per share of 0.16 yuan [2] - In contrast, the revenue for the same period in 2024 was about 256 million yuan, with a net loss attributable to shareholders of approximately 10.36 million yuan and a basic loss per share of 0.01 yuan [2]